Scientific Committee on Consumer Safety

SCCS

**OPINION ON**

*Hydroxyethyl-p-phenylenediamine sulfate*

**COLIPA n° A80**

The SCCS adopted this opinion at its 6th plenary meeting of 23 March 2010
About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are: the Scientific Committee on Consumer Safety (SCCS), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCS

The Committee shall provide opinions on questions concerning all types of health and safety risks (notably chemical, biological, mechanical and other physical risks) of non-food consumer products (for example: cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products such as detergents, etc.) and services (for example: tattooing, artificial sun tanning, etc.).

Scientific Committee members

Jürgen Angerer, Ulrike Bernauer, Claire Chambers, Qasim Chaudhry, Gisela Degen, Gerhard Eisenbrand, Corrado Galli, Thomas Platzek, Suresh Chandra Rastogi, Vera Rogiers, Christophe Rousselle, Tore Sanner, Kai Savolainen, Jacqueline Van Engelen, Maria Pilar Vinardell, Rosemary Waring, Ian R. White

Contact

European Commission
Health & Consumers
Directorate C: Public Health and Risk Assessment
Unit C7 - Risk Assessment
Office: B232     B-1049 Brussels
Sanco-Sc6-Secretariat@ec.europa.eu

© European Union, 2010
doi:10.2772/22604                    ND-AQ-09-005-EN-N

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm
ACKNOWLEDGMENTS

Prof. J. Angerer
Dr. C. Chambers
Prof. G. Eisenbrand
Prof. T. Platzek Chairman
Dr. S.C. Rastogi
Dr. C. Rousselle
Prof. T. Sanner
Dr. J. van Benthem associated member
Prof. M.P. Vinardell
Dr. I.R. White rapporteur

External experts

Dr. Mona-Lise Binderup COWI A/S, Denmark

This opinion has been subject to a commenting period of four weeks after its initial publication. All comments received during this time have been considered by the SCCS and discussed in the subsequent plenary meeting. Where appropriate, the text of the relevant sections of the opinion has been modified or explanations have been added. In the cases where the SCCS after consideration and discussion of the comments, has decided to maintain its initial views, the opinion (or the section concerned) has remained unchanged.

Keywords: SCCS, scientific opinion, hair dye, hydroxyethyl-p-phenylenediamine sulfate, CAS 93841-25-9, EC 298-995-1, directive 76/768/EEC

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on hydroxyethyl-p-phenylenediamine sulfate, 23 March 2010
Opinion on hydroxyethyl-p-phenylenediamine sulfate

TABLE OF CONTENTS

ACKNOWLEDGMENTS ................................................................. 3

1. BACKGROUND ................................................................. 5

2. TERMS OF REFERENCE ...................................................... 6

3. OPINION ....................................................................... 6

4. CONCLUSION ................................................................. 26

5. MINORITY OPINION ......................................................... 26

6. REFERENCES ................................................................. 27
1. BACKGROUND

Submission I for Hydroxyethyl-p-phenylenediamine sulfate was submitted in February 1989 by COLIPA \(^1\) according to COLIPA.

The first scientific opinion was adopted the 19 of February 1991 by the Scientific Committee on Cosmetology (SCC) with the conclusion that:

“The SCC requires an adequate study for the induction of gene mutations in Salmonella assay.”

Submission II for Hydroxyethyl-p-phenylenediamine sulfate was submitted in March 1992 by COLIPA.

The second opinion was adopted the 10 of December 1993. The SCC repeated its conclusion from the former opinion.

Submission III for Hydroxyethyl-p-phenylenediamine sulfate was submitted in August 2001 by COLIPA according to COLIPA.

The third opinion (SCCP/0666/03) was adopted the 7 December 2004 by the SCCP with the conclusion that: “The information submitted is inadequate to assess the safe use of the substance. Before any further consideration, the following information is required: * complete physico-chemical characterisation of the test substances used, including data on stability, * data on percutaneous absorption following the SCCNFP Notes of Guidance, * data on the genotoxicity/mutagenicity following the relevant SCCNFP opinions and in accordance with the Notes of Guidance.”

Submission IV for this substance was submitted in July 2005 by COLIPA.

The fourth opinion (SCCP/1124/07) was adopted the 30 September 2008 with the conclusion: “Based on the information provided, a margin of safety of 74 has been calculated suggesting that the use of hydroxyethyl-p-phenylenediamine sulfate as an oxidative hair dye at a maximum concentration of 1.5% in the finished cosmetic product (after mixing with hydrogen peroxide) poses a risk to the health of the consumer. The in vitro dermal absorption study was not carried out according to the basic criteria for dermal absorption of the SCCP (SCCP 0970/06). Therefore, for the safety assessment, the absorption as determined in the in vivo ADME study was used in the calculation of the MOS. It is known that dermal absorption through rat skin is higher than that through human skin.

The conclusion may be re-evaluated if an adequately performed in vitro dermal absorption study is available.

*Hydroxyethyl-p-phenylenediamine sulfate is a strong sensitiser. Hydroxyethyl-p-phenylenediamine sulfate itself has no mutagenic potential in vivo. However, studies on genotoxicity/mutagenicity in finished hair dye formulations should be undertaken following the relevant SCCNFP/SCCP opinions and in accordance with its Notes of Guidance.”

The current submission V consists of a new dermal penetration study. The intended use concentration was increased to a maximum of 2.0% on-head.

\(^1\) COLIPA - European Cosmetics Toiletry and Perfumery Association
2. TERMS OF REFERENCE

1. In the light of the current data submission and the available data base from previous submissions does the SCCS consider Hydroxyethyl-p-phenylenediamine sulfate safe for use as an oxidative hair dyes with a concentration on-head of maximum 2.0% taken into account the new dermal penetration study provided?

2. And/or does the SCCS have any further scientific concerns with regard to the use Hydroxyethyl-p-phenylenediamine sulfate in oxidative hair dye?

3. OPINION

3.1. Chemical and Physical Specifications

*Taken from SCCP/1124/07*

### 3.1.1. Chemical identity

3.1.1.1. Primary name and/or INCI name

Hydroxyethyl-p-phenylenediamine sulfate (INCI)

3.1.1.2. Chemical names

Benzeneethanol, 2,5-diamino-, sulfate (1:1) (salt) (CA index name, 9CI)
2-(2,5-Diaminophenyl)ethanol sulfate (1:1) (IUPAC)
3-(2-hydroxyethyl)-p-phenylenediammonium sulfate

3.1.1.3. Trade names and abbreviations

Betoxol
COLIPA n° A80

3.1.1.4. CAS / EC number

CAS: 93841-25-9
EC: 298-995-1

3.1.1.5. Structural formula

![Structural formula](image)

3.1.1.6. Empirical formula

Formula: C₈H₁₂N₂O . H₂SO₄
### 3.1.2. Physical form

Grey powder

### 3.1.3. Molecular weight

Molecular weight: 250.28 g/mol

### 3.1.4. Purity, composition and substance codes

<table>
<thead>
<tr>
<th>Description \ Batch</th>
<th>WE 51</th>
<th>WE 68</th>
<th>100789 (R96003795)</th>
<th>30/01 (R0012730)</th>
<th>36/37 (R0024480)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification</td>
<td>NMR, HPLC</td>
<td>NMR, HPLC</td>
<td>NMR, HPLC</td>
<td>NMR, HPLC</td>
<td>NMR, HPLC</td>
</tr>
<tr>
<td>NMR content / %, w/w</td>
<td>99.1</td>
<td>99.0</td>
<td>98.3</td>
<td>99.6</td>
<td>99.9</td>
</tr>
<tr>
<td>HPLC purity / area %**</td>
<td>99.7</td>
<td>99.7</td>
<td>99.4</td>
<td>99.8</td>
<td>99.8</td>
</tr>
<tr>
<td>210 nm</td>
<td>99.9</td>
<td>99.9</td>
<td>99.7</td>
<td>99.9</td>
<td>99.8</td>
</tr>
<tr>
<td>254 nm</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>99.8</td>
</tr>
<tr>
<td>292 nm</td>
<td>94.7</td>
<td>95.6</td>
<td>97.4</td>
<td>98.1</td>
<td>98.8</td>
</tr>
<tr>
<td>HPLC content* / %, w/w</td>
<td>94.7</td>
<td>95.6</td>
<td>97.4</td>
<td>98.1</td>
<td>98.8</td>
</tr>
<tr>
<td>Impurities (content in ppm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Phenylenediamine</td>
<td>151</td>
<td>149</td>
<td>100</td>
<td>190</td>
<td>71</td>
</tr>
<tr>
<td>2-Methyl-1,4-benzenediamine</td>
<td>93</td>
<td>90</td>
<td>40</td>
<td>40</td>
<td>29</td>
</tr>
<tr>
<td>Metanilic acid</td>
<td>&lt; 10°</td>
<td>&lt; 10°</td>
<td>&lt; 10°</td>
<td>&lt; 10°</td>
<td>&lt; 20°</td>
</tr>
<tr>
<td>Water content, % (w/w)</td>
<td>0.09</td>
<td>0.09</td>
<td>0.1</td>
<td>0.07</td>
<td>0.16</td>
</tr>
<tr>
<td>Loss on drying, % (w/w)</td>
<td>0.04</td>
<td>0.02</td>
<td>&lt; 0.1</td>
<td>0.07</td>
<td>0.03</td>
</tr>
<tr>
<td>Sulfated ash, % (w/w)</td>
<td>0.02</td>
<td>0.02</td>
<td>0.05</td>
<td>0.01</td>
<td>0.16</td>
</tr>
<tr>
<td>Content of H2SO4, % (w/w)</td>
<td>39.1</td>
<td>39.1</td>
<td>39.2</td>
<td>***</td>
<td>39.1</td>
</tr>
<tr>
<td>Element screening / ppm</td>
<td>Na: 37</td>
<td>Na: 32</td>
<td>Na: 34</td>
<td>***</td>
<td>Na: 241</td>
</tr>
<tr>
<td>Si: 57</td>
<td>Si: 60</td>
<td>Si: 37</td>
<td>Si: 29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The HPLC content refers to R0029 (100789 (R96003795)) with 99.9%, w/w; for each indicated value three measurements were made with a rather high standard deviation (always one measurement rather low)

** HPLC conditions: LiChrosphere 60 RP Select B; mobile phase consisting of ACN: buffer (KH2PO4 (0.02 M) + pentanesulfonic acid (0.01 M), pH 5.5) (5:95); Flow rate: 1 ml/min

*** not determined because lack of substance

° not detected, shown value indicates limit of detection

### 3.1.5. Impurities / accompanying contaminants

See 3.1.4

**Solvent residues**
Solvents, (i.e. solvents such as methanol, ethanol, isopropanol, n-propanol, acetone, ethyl acetate, cyclohexane, methyl ethyl ketone and monochlorobenzene < 100 ppm) were not detected.

### 3.1.6. Solubility

<table>
<thead>
<tr>
<th>Solution</th>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>51.2 g/L (20 °C, pH 2.02)</td>
<td>(measured according to EU method A6)</td>
</tr>
<tr>
<td>DMSO</td>
<td>4.6% (w/w)</td>
<td></td>
</tr>
<tr>
<td>Acetone/water 1:1</td>
<td>0.3% (w/w)</td>
<td></td>
</tr>
</tbody>
</table>

### 3.1.7. Partition coefficient (Log P<sub>ow</sub>)

Log P<sub>ow</sub>: 0.07 (measured according to EU method A8)
### 3.1.8. Additional physical and chemical specifications

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melting point</td>
<td>250 °C (decomposition)</td>
<td>(EU – A.1)</td>
</tr>
<tr>
<td>Boiling point</td>
<td>decomposition at melting point</td>
<td>(EU – A.2)</td>
</tr>
<tr>
<td>Flash point</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>5.54 x 10^{-11} hPa (20°C)</td>
<td>(EU - A.4)</td>
</tr>
<tr>
<td>Density</td>
<td>1.50 g/ml (20°C)</td>
<td>(EU - A.3)</td>
</tr>
<tr>
<td>Viscosity</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>pKa</td>
<td>15.12 for R-CH$_2$OH (acidic)</td>
<td>calculated</td>
</tr>
<tr>
<td></td>
<td>6.51 for R-C$_6$H$_4$-NH$_3$(^+) (basic)</td>
<td>calculated</td>
</tr>
<tr>
<td>Refractive index</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>2.02 (saturated aqueous solution, 20°C)</td>
<td>(Reference 5)</td>
</tr>
<tr>
<td>UV_Vis spectrum</td>
<td>/</td>
<td></td>
</tr>
</tbody>
</table>

### 3.1.9. Stability

The test substance is considered to be stable for more than 3 years, if stored dry and protected from light at room temperature.

The stability of an approximately 5% (w/w) solution of hydroxyethyl-p-phenylenediamine sulfate in water and approximately 2% (w/w) in DMSO was tested over a period of 7 days. The test solutions were stored at room temperature and in the absence of light. The test material was stable in these solutions over the period of seven days (Recovery: 95.5-100% of the original concentration).

**General Comments to physico-chemical characterisation**

- The stability of hydroxyethyl-p-phenylenediamine sulfate in the marketed products is not reported.

### 3.2. Function and uses

Hydroxyethyl-p-phenylenediamine sulfate is used as an oxidative hair colouring agent. The intended maximum on-head concentration is 2%.
3.3. Toxicological Evaluation

3.3.1. Acute toxicity

3.3.1.1. Acute oral toxicity

_Taken from SCCP/1124/07_

| Guideline: | / |
| Species/strain: | Wistar rat (SPF); CF1 mice (SPF) |
| Group size: | 5 male + 5 female rats; 10 female mice |
| Test substance: | Hydroxyethyl-p-phenylenediamine dihydrochloride |
| Purity: | / |
| Batch: | / |
| Dose levels: | rat: 50, 100, 200, 300 and 400 mg/kg bw/day |
| | Mice: 50, 100 and 150 mg/kg bw |
| Route: | oral (gavage) |
| Observation period: | 14 days |
| GLP: | not in compliance |

A 1.0% aqueous test solution was administered by gavage to 25 female (circa 187 g) and 25 male (circa 194 g) Wistar rats and 50 female CF1 mice (circa 26 g). Single doses of 50, 100, 200, 300 and 400 mg/kg bw were administered to groups of 5 male and 5 female rats; single doses of 50, 100 and 150 mg/kg bw to groups of 10 female mice. During the observation period of 14 days, mortalities and signs of toxicity were recorded. All animals were dissected.

Results

20 minutes after administration, the test compound caused moderate sedation and ataxia. No changes were observed in organs. The LD50 was calculated as 150 mg/kg bw in male and female rats and as 90 mg/kg bw in mice. The substance was considered to be moderately toxic.

Ref.: 17

Comment

The experiment was not performed in compliance with guidelines. It was performed with the dihydrochloride instead of the sulfate salt.

| Guideline: | OECD 401 (1987) |
| Species/strain: | Mice/strain Him:OFI |
| Group size: | 10/group (5 males and 5 females) |
| Test substance: | hydroxyethyl-p-phenylenediamine (1,4-diamino-2-ß-hydroxyethylbenzene-sulfate) |
| Batch: | Not indicated |
| Purity: | > 98% (according to the supplier) |
| Dose: | 20, 36, 63, 112 and 200 mg/kg bw |
| Route: | oral (by gavage) |
| Exposure: | Once (in the morning), followed by a observation period of 2 weeks |
| GLP: | in compliance |
| Date: | July-August 1990 |

Five groups of 10 male and 10 female mice received the test item, once by gavage at 20, 36, 63, 112 or 200 mg/kg bw. This dosage-range was based on a preliminary study, in which all animals (4/4) died after receiving 200 or 2000 mg/kg bw hydroxyethyl-p-phenylenediamine. Hydroxyethyl-p-phenylenediamine was dissolved in distilled water.
Behaviour, reactions and physical signs of the animals were observed and findings were recorded at 1, 10, 30 min, 1, 2, 4 and 6 hours post administration and then at least once a day for 2 weeks. Body weight was determined before administration, and 7 and 14 days post administration. Any found dead animal was dissected and submitted to a macroscopic post-mortem examination in order to identify the target organs. All surviving animals were sacrificed by CO₂ asphyxiation at 14 days post administration and examined macroscopically.

Results
All animals in the 112 or 200 mg/kg bw group died early. Death occurred between 1 hr-4 days in the 112 mg/kg bw group and between 30 min-2 hr in the 200 mg/kg bw group. 1/10 of the animals in the 63 mg/kg bw died within 4 hr post administration.

No effects on body weight and body weight gain were observed. All animals showed signs of malaise (e.g. decreased motor activity, ruffled fur, closed eyes, hunched posture, decreased muscular tension or unconsciousness). In some animals ataxia, dyspnoea or low grade convulsions were observed. Effects diminished and returned to normal within 6hr – 1wk post administration. 7/20 of the animals that died early did not show any clinical signs at the post-mortem examination. Most of the other animals that died early showed signs of shock due to severe gastrointestinal irritations or hepatotoxicity.

Conclusions
Under the experimental conditions of this study, the LD50 was 80 mg/kg bw (71-89 mg/kg bw 95% CI), calculated for both sexes combined.

Ref.: 18

3.3.1.2. Acute dermal toxicity
No data submitted

3.3.1.3. Acute inhalation toxicity
No data submitted

3.3.2 Irritation and corrosivity

3.3.2.1. Skin irritation

**Taken from SCCP/1124/07**

Guideline: /
Species: Guinea pig, strain White Pirbright (SPF)
Group: 15 females
Substance: 1-β-hydroxyethyl-2,5-diaminobenzene dihydrochloride
Batch: /
Purity: /
Dose: 3% aqueous dilution thickened with 0.5% tylose
Vehicle: water
GLP: not in compliance
Date: 11 – 18 March 1985

A 3% dilution of 1-β-hydroxyethyl-2,5-diaminobenzene dihydrochloride in 0.5% aqueous tylose was applied onto the clipped flank region of 15 albino guinea pigs by means of a brush daily for 5 consecutive days. The skin was not covered, but animals were restrained from movement in order to avoid contact with the treated area (3 x 4 cm) during the first 5 hours after application. Possible skin reactions were evaluated for erythema and oedema 5 hours after each application.
Results
No skin reactions at all were observed at any observation time point.

Conclusion
No indication of a skin irritating potential of 1-β-hydroxyethyl-2,5-diaminobenzene dihydrochloride tested at a 3% aqueous solution in a repeated application assay in guinea pigs was noted.

Comment
Although the experiment was not in compliance with guidelines and performed with the dihydrochloride instead of the sulfate, the data indicates that 1-β-hydroxyethyl-2,5-diaminobenzene dihydrochloride is not irritant to guinea pig skin at concentrations up to 3%. This applies probably also for the sulfate.

3.3.2.2. Mucous membrane irritation

*Taken from SCCP/1124/07*

**Guideline:** OECD 405  
**Species:** Rabbit, strain Albino New Zealand White (SPF)  
**Group:** 3 males  
**Substance:** Betoxol  
**Batch:** “J. Robinson 10.7.89”  
**Purity:** 99.7%  
**Dose:** 60mg (0.1 ml), without rinsing  
**Vehicle:** water to form paste  
**GLP:** In compliance  
**Date:** 17 November – 1 December 1999

A single sample of 0.1 ml of an aqueous paste of Betoxol containing 60 mg of the test item was applied into the conjunctival sac of the left eye of 3 male rabbits; the right eye served as control. The eyes were not rinsed, and evaluated and scored 1, 24, 48, and 72 hours as well as 7 and 14 days after application. Further readings by means of fluorescein-instillation took place 24 h and 48 h after substance application.

Results
Iridial irritation (grade 1 on a scale from 1-4) was observed in all animals after 1 and 24 hours. Irritation of the conjunctiva was seen as redness, chemosis and discharge, which had completely resolved within 7 days in two animals and within 14 days in one animal. No corneal opacity was observed, and treatment of the eyes with 2% fluorescein revealed no corneal epithelial damage in any of the animals. There was no evidence of ocular corrosion. No staining of peri-ocular tissues by the test item was observed.

Conclusion
Under the conditions of the test, undiluted Betoxol was irritant to rabbit eyes.

3.3.3. Skin sensitisation

*Taken from SCCP/1124/07*

**Local Lymph Node Assay (LLNA)**

**Guideline:** OECD 406  
**Species:** Mouse, strain CBA/Ca01aHsd
The skin sensitising potential of hydroxyethyl-p-phenylenediamine sulfate was investigated in CBA/Ca01aHsd mice by measuring the cell proliferation in the draining lymph nodes after topical application on the ear. 3 test groups (3 different concentrations), 1 positive control group and 1 negative control (vehicle) group were tested. Twenty five µl of 0 (vehicle only), 0.5, 1.0 and 2.0% of hydroxyethyl-p-phenylenediamine sulfate in DMSO were applied to the dorsal surface of the ear to each of five mice per group for three consecutive days. p-Phenylenediamine (PPD) at 1% in DMSO was used as the positive control in parallel under identical test conditions. On day 5, the mice received an intravenous injection into the tail vein of 250 µl phosphate buffered saline containing 20.0 µCi of [H3] methyl thymidine. Approximately five hours later, the mice were sacrificed by CO2-inhalation and the draining auricular lymph nodes were removed and weighed. After preparing a single cell suspension for each mouse, cells were precipitated by TCA and the radioactivity was determined (incorporation of [H3] methyl thymidine in the pellets) by means of liquid scintillation counting as disintegrations per minute (dpm). The mean dpm per treated group was determined and the stimulation index (test item compared to the concurrent vehicle control) was calculated. The proliferative response of lymph node cells was calculated as the ratio of 3H-methyl thymidine-incorporation into lymph node cells of test group animals relative to that recorded for control group animals. A stimulation index, ratio of test substance / vehicle control, was calculated for each concentration.

Results
The mean stimulation indices were affected in a dose-dependent manner by the treatment with hydroxyethyl-p-phenylenediamine sulfate. With the test item in DMSO, mean stimulation indices of 2.8, 4.5 and 7.0 were obtained for the 3 test concentrations of 0.5, 1.0 and 2.0%, respectively. An EC3 value (equal to the concentration inducing a stimulation index of 3) of 0.57% for hydroxyethyl-p-phenylenediamine sulfate was calculated. The positive control (PPD, 1% in DMSO) caused a stimulation index of 10.1.

Conclusion
Hydroxyethyl-p-phenylenediamine sulfate induced a biologically relevant immune response in local lymph nodes after dermal application to the mouse ear when DMSO was used as vehicle. The EC3 value was 0.57%. The concurrent positive control demonstrated the sensitivity of the assay.

Based on these findings hydroxyethyl-p-phenylenediamine sulfate is evaluated to be a skin-sensitiser under the described test conditions.

Ref.: 22

Comment
According to the grading scheme used by SCCS (SCCP/0919/05), hydroxyethyl-p-phenylenediamine sulfate is a strong skin sensitiser

The previous submission contained a Magnusson-Kligman Maximisation test performed with hydroxyethyl-p-phenylenediamine sulfate, but the test design was not in line with current
scientific and regulatory requirements. Specifically the concentrations used for both, the epidermal induction and the challenge were not based on the required thresholds for a minimum irritating/maximum non-irritating concentration. In addition, unspecified test material was used. The study results suggested that there was no indication of a sensitising potential of hydroxyethyl-p-phenylenediamine sulfate. Ref.: 4 (subm. I)

Conclusion
In the local lymph node assay, hydroxyethyl-p-phenylenediamine sulfate induced a biologically relevant immune response in the vehicle DMSO with an EC3 value of 0.57%, indicative of a strong sensitiser.

Human data

From 1993 to 2003, 1235 individuals with a known history of contact allergy to p-phenylenediamine (PPD) and/or toluene-2,5-diamine (PTD) were recruited and of these data on further testing were available from a cohort of 1079 subjects.

The individuals in the cohort were asked to choose 2-3 shades from a range of colours that contained between 0.015 – 5.0% A80 (which would equate to on hair concentration of 0.0075 – 2.5% when mixed 1:1 with peroxide) but did not contain PPD or PTD.

The chosen shades were diluted 1:10 and 1:100 and used for patch testing.

It was reported that 76% of tested subjects produced no reaction, 20% a positive reaction, 3% an irritant reaction and 1% had a reaction on subsequent exposure. Of the 21% (231 subjects), 41 had further tests to the several ingredients of the A80-containing hair dye formulation and 19 reacted to A80 (1% pet.).

The study authors concluded that A80 may be a useful solution to the problem of PPD/PTD contact allergy.

Comment
Description of the methodology and data is limited. The colour shade preferences (and A80 content) used is not stated. The patch test concentrations may have been too low. The grade of patch test reactions experienced by the cohort to PPD/PTD is not stated; this is important.

The data confirm that A80 is a contact allergen in man. Ref.: 33

3.3.4. Dermal / percutaneous absorption

Submission November 2009

Tissue: 8 samples of full-thickness human (7 abdomen and 1 breast)
Membrane: split-thickness membranes at 200 – 400 µm
Group size: 12 samples from 6 different donors per experiment
Diffusion cells: flow-through diffusion cells, 0.64 cm²
Skin integrity: tritiated water, permeability coefficient < 3.5 x 10⁻³ cm/h
Test substance: hydroxyethyl-p-phenylenediamine sulfate (Betoxol II)
Batch: 36/37 (R0024480)
Purity: 99.8 area% (HPLC)
Radiolabel hydroxyethyl-p-[ring-U-¹⁴C]phenylenediamine sulfate; 242 µCi/mg
Radiolabel batch CFQ40510 batch B1
Hydroxyethyl-p-phenylenediamine sulfate was incorporated into a typical oxidative hair dye formulation at ca 4% (w/w), before mixing with developer containing H₂O₂ ((1:1, w/w)-test preparation 1) or placebo developer ((1:1, w/w)-test preparation 2). The concentration of Hydroxyethyl-p-phenylenediamine sulfate in the test preparations applied to the skin was ca 2% (w/w).

Two test preparations containing [¹⁴C]-Hydroxyethyl-p-phenylenediamine sulfate were prepared and applied, at an application rate of ca 20 mg/cm², to human split-thickness skin membranes mounted into flow-through diffusion cells in vitro.

Absorption was assessed by collecting receptor fluid in 30 min fractions from 0 to 1 h post dose, then hourly fractions from 1 to 6 h post dose and then in 2-hourly fractions from 6 to 72 h post dose. At 30 min post dose, the skin was washed with water, sodium dodecyl sulphate (SDS) solution (2% w/v) and water again. The skin was then dried with tissue paper swabs. At 72 h post dose, the skin surface was washed and dried in the same manner as described for the 30 min wash. The underside of the skin was rinsed with receptor fluid.

The skin was then removed from the flow-through cells, dried and the stratum corneum removed by tape stripping. The remaining samples were divided into exposed and unexposed skin (i.e. the area of skin under the cell flange). The exposed epidermis was separated from the dermis using heat separation. The skin samples were solubilised with Solvable® tissue solubiliser. All liquid samples were analysed by liquid scintillation counting.

For [¹⁴C]-Hydroxyethyl-p-phenylenediamine sulfate in the oxidative hair dye test preparation at a concentration of 2% (w/w) (Test Preparation 1), a total of 12 samples of human skin, obtained from 6 different donors were dosed topically with [¹⁴C]-Hydroxyethyl-p-phenylenediamine sulfate. At 30 min post dose, 97.16% of the applied dose was removed by washing. At 72 h post dose and after the final wash off, the stratum corneum retained 0.80% (3.48 μg equiv./cm²) of the applied dose. The epidermis and dermis retained 0.37% (1.63 μg equiv./cm²) and 0.06% (0.25 μg equiv./cm²) of the applied dose, respectively. The absorbed dose or the amount that had penetrated through the skin (receptor fluid and receptor rinse) was 0.13% (0.58 μg equiv./cm²) of the applied dose. The mass balance was complete with 99.59% (SD 1.91%) of the applied dose recovered.

For [¹⁴C]-Hydroxyethyl-p-phenylenediamine sulfate in the non-oxidative hair dye test preparation at a concentration of 2% (w/w) (Test Preparation 2), a total of 12 samples of human skin, obtained from 6 different donors were dosed topically with [¹⁴C]-Hydroxyethyl-
Opinion on hydroxyethyl-p-phenylenediamine sulfate

At 30 min post dose, 99.17% of the applied dose was removed by washing. At 72 h post dose and after the final wash off, the stratum corneum retained 0.53% (2.26 μg equiv./cm²) of the applied dose. The epidermis and dermis retained 0.27% (1.16 μg equiv./cm²) and 0.06% (0.26 μg equiv./cm²) of the applied dose, respectively. The absorbed dose or the amount that had penetrated through the skin (receptor fluid and receptor rinse), was 0.16% (0.70 μg equiv./cm²) of the applied dose. The mass balance was complete with 101.21% (SD 3.08%) of the applied dose recovered.

Summary table

<table>
<thead>
<tr>
<th>Test Preparation</th>
<th>1 (oxidative)</th>
<th>2 (non-oxidative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target test item concentration (%, w/w)</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Concentration of Test Item by Radioactivity (%, w/w)</td>
<td>2.04</td>
<td>2.09</td>
</tr>
<tr>
<td>Total Dislodgeable Dose</td>
<td>% applied dose</td>
<td>μg equiv./cm²</td>
</tr>
<tr>
<td>Stratum Corneum</td>
<td>98.22</td>
<td>427.68</td>
</tr>
<tr>
<td>Epidermis</td>
<td>0.80</td>
<td>3.48</td>
</tr>
<tr>
<td>Dermis</td>
<td>0.37</td>
<td>1.63</td>
</tr>
<tr>
<td>Receptor Fluid</td>
<td>0.06</td>
<td>0.25</td>
</tr>
<tr>
<td>Dermal Bioavailability (range)</td>
<td>0.57 ± 0.27</td>
<td>2.46 ± 1.16</td>
</tr>
<tr>
<td>Mass Balance</td>
<td>99.59</td>
<td>433.64</td>
</tr>
</tbody>
</table>

Epidermis = the sum of the epidermis and cling film
Receptor Fluid = the sum of the receptor fluid and receptor rinse

Conclusion
The study authors concluded that the dermal bioavailability of hydroxyethyl-p-phenylenediamine sulfate was 0.57% (2.46 μg equiv./cm²) under oxidative conditions and 0.49% (2.12 μg equiv./cm²) under non-oxidative conditions.

Comment
This was a well performed study. For calculating the MoS under oxidative conditions the amount bioavailable is considered as 3.62 μg equiv./cm² (mean + 1 SD, 2.46 + 1.16 equiv./cm²). Under non-oxidative conditions the amount bioavailable is considered as 3.17 μg equiv./cm² (mean + 1SD, 2.12 + 1.05 equiv./cm²).

3.3.5. Repeated dose toxicity

3.3.5.1. Repeated Dose (28 days) oral / dermal / inhalation toxicity

Taken from SCCP/1124/07

Species/strain: Rats/strain Wistar CRL:(WI) BR
Group size: 10 animals (5 males and 5 females) per dose group
Test substance: Oxytol-B-sulfate (betoxolsulfate) 4% in kolleston 2000
Batch: /
Purity: >98% (according to the supplier)
Dose: 0, 62.5, 250 and 1000 mg/kg bw
Route: dermal
Exposure: once a day on 5 days/week for 28 consecutive days
GLP: in compliance
Study period: 26 September 1990 (first dosing)

Three groups (5 male and 5 female rats) received oxytol-B-sulfate in a concentration of 0 (vehicle only), 62.5, 250 or 1000 mg/kg bw once a day on 5 days per week for 28 consecutive days. This dose-range was based on a preliminary study, in which a non-
significant reduction in body weight and food consumption was observed at a dose of 2000 mg/kg bw. The NOEL of this study was 500 mg/kg bw. Oxytol-B-sulfate was dissolved in distilled water.

Dermal administration was performed once a day on 5 days per week, on an area of the dorsal skin of about 5 cm x 6 cm, which is at least 10 % of the body surface. Hair of this region was clipped before first administration and then once a week. The test substance preparation was applied and spread using a plastic spatula. As far as necessary, some drops of distilled water were applied additionally to allow a distribution of the test substance on the whole administration area. The treated area was covered with a cellulose patch, which was held in place by an adhesive tape. Cellulose patch, tape and residual test substance were removed after 6 hours.

A negative control group (5 male and 5 female rats) did not receive the test item, but was treated with the same cellulose patch and adhesive tape as the dosed animals. In addition, two groups (5 male and 5 female rats) were treated with 0 or 1000 mg/kg BW in the same way as their corresponding groups, but were kept then for a further 14 days without test substance administration in an attempt to observe regression or progression of test substance induced lesions.

All animals were observed for clinical signs, behavioural changes and dermal alterations at least once per day. Body weight and feed consumption was determined regularly. Other investigations were ophthalmoscopy, haematology and clinical chemistry. Animals were killed by CO2 and subjected to necroscopy including gross pathological examination, organ-weight determination, histopathological examination and treated and untreated skin was dermally examined for erythema and oedema.

Results
Staining of skin, fur and bedding material in all dosed animals was observed: the incidence and the intensity of the staining increased with dose indicating that the staining was most probably due to oxytol-B-sulfate. These effects are regarded non-toxic.

No significant effect on body weight, organ weight and feed consumption was observed. No dose-related abnormalities with respect to ophthalmoscopy were observed. Chromodacryorrhoea (excessive secretion of coloured tears) was observed with increased dose.

In the 1000 mg/kg bw/day dose group 3/10 animals showed acanthosis indicating local irritation. In one of the animals showing acanthosis also an ulcer was observed. No other histopathological alterations were found.

Conclusions
Based on the local effects in this study the NOAEL was 250 mg/kg bw/day for both sexes. The NOAEL for systemic effects is 1000 mg/kg bw/day.

Ref.: 24

Comments
The test substance solution was not tested for stability.

3.3.5.2. Sub-chronic (90 days) oral / dermal / inhalation toxicity

Taken from SCCP/1124/07

Species/strain: Rats / CRL:(WI) BR Wistar
Group size: 20 animals (10 males and 10 females) per dose group
Test substance: hydroxyethyl-p-phenylenediamine sulfate (Betoxol II), in 1% aqueous methylcellulose (as a suspension)
Batch: 36/37
Purity: ~99.8%
Dose: 0 (vehicle only), 25, 35 and 55 mg/kg bw/day
Route: oral, by gavage
Opinion on hydroxyethyl-p-phenylenediamine sulfate

Exposure: daily for 90 consecutive days
GLP: in compliance
Study period: 16 November 2004 – 15 February 2005

CRL:(WI) BR Wistar rats (n=10/sex/group) were treated daily on a 7/days/week basis by gavage with the test item at a dose of 0, 25, 35 and 55 mg/kg bw. This dose-range was based on data from a preliminary study which showed that a dose of 75 mg/kg bw/day caused significant body weight stagnation, body weight gain depression and decreased food consumption. In this range-finding study, the test item was found to cause an increase in AST activity at doses of 40 mg/kg bw/day (in females) and 60 mg/kg bw/day (in males and females).

In the 90-day oral toxicity study the test item was prepared in 1% aqueous methylcellulose, corresponding to a constant treatment volume of 10 ml/kg bw. The concentration of dosing suspensions was analysed on days 0, 7 and 90.

Mortality and morbidity of treated animals were checked twice daily, clinical observations were made once per day. Once before the first exposure, once a week thereafter and once on week 12, a modified Irwin test was performed, which included a functional observation battery (evaluation of reaction of auditory, visual and proprioceptive stimuli and assessment of grip strength and motor activity). Ophthalmoscopy was performed before treatment and in the control and 55 mg/kg bw dose groups on week 12.

Haematological examinations and clinical biochemical analyses were conducted before the first treatment and one day after the last treatment. Urinalysis was performed in week 11. Animals were killed by pentobarbital and subjected to necroscopy including gross pathological examination, organ-weight determination and histopathology.

Results
No clinical signs have been recorded which were considered to be related to a toxic effect of the test substance. No difference was found between the experimental groups with respect to performance in the functional observational test battery before starting the study, one week thereafter and at termination of the study. Effects on body weight gain were observed, but these effects were not dose-related. Mean daily food consumption was comparable between the control and dosed groups. Ophthalmoscopy did not show any test item related alterations. Haematology showed some variations in RC, PT, WBC, SE, LY and RBC, but these effects were not dose-related. In the 55 mg/kg bw/day dose group, a test item-related and statistically and biologically significant increase in activity of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was found in male and especially in female animals. Histopathology did not reveal dose-related lesions of the examined organs.

Conclusion
Hydroxyethyl-p-phenylenediamine sulfate induced an increase in the AST and ALT activities in CRL:(WI) BR rats at a dose of 55 mg/kg bw/day for 90 days. The NOAEL in this study was 35 mg/kg bw.

Ref.: 25

3.3.5.3. Chronic (> 12 months) toxicity
No data submitted

3.3.6. Mutagenicity / Genotoxicity

3.3.6.1 Mutagenicity / Genotoxicity in vitro

Taken from SCCP/1124/07

Bacterial Reverse Mutation Test
Species/strain: Salmonella typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
Replicates: Triplicates in two independent experiments
Test substance: Hydroxyethyl-p-Phenylenediamine Sulfate (WR 23361)
Solvent: Deionised water
Batch: 36/37
Purity: 99.8 area% (by HPLC)
Concentrations: Exp. I and II: 33, 100, 333, 1000, 2500 and 5000 µg/plate
Exp IIa: 1000, 1500, 2000, 2500, 3000, 3500, 4000 and 5000 µg/plate (TA100 without S9-mix only)
Treatment: Experiment I: Standard plate incorporation assay
Experiment II: Pre-incubation assay
Both assays with and without Phenobarbital/β-Naphthoflavone induced rat liver S9-mix
GLP: in compliance
Study period: 6 December 2004 – 17 February 2005

To evaluate the toxicity of the test item a pre-study was performed with strains TA 98 and TA 100. Eight concentrations were tested up to 5000 µg/plate. The plates showed normal background growth up to 5000 µg/plate and there were no signs of toxicity, evident as a reduction in the number of revertants.

Results
A reduction in the number of revertants occurred in experiment II with metabolic activation in strain TA 1535 at 1000 µg/plate and in strain TA 1537 at 100 µg/plate and 333 µg/plate. Because this reduction was not dose dependent, it was not judged as a true toxic effect.

In both experiments, there were no indications of an increase in the mutant frequency at any concentration in the tester strains either with or without metabolic activation. The only exception was TA 100 in experiment two without metabolic activation at 2500 µg/plate. The number of revertants exceeded a doubling of the control value. No dose-dependency was observed, however, a confirmatory experiment was performed (IIa). This assay showed increases at 1500 and 4000 µg/plate compared to the control and the range of historical solvent and negative control were slightly exceeded. At both concentrations, a doubling of the number of revertants compared to the control was not achieved and the increases were not dose dependent. Therefore, the increases were not considered as biological relevant.

Conclusion
Under the test conditions used Hydroxyethyl-p-Phenylenediamine Sulfate (WR 23361) did not induce gene mutations in bacteria.

Comment
The historical range was slightly exceeded in the solvent control in both experiments of strain TA 102 with metabolic activation. In experiment one, the historical range was slightly exceeded in strain TA1535 (negative control) without metabolic activation. However, these findings did not influence the conclusion.

In vitro Mammalian Cell Gene Mutation Test (hprrt- locus)
Guideline: OECD 476 (1997)
Species/strain: V79 Chinese Hamster cells
Replicates: Two independent experiments with duplicate cultures
Test substance: Hydroxyethyl-p-Phenylenediamine Sulfate (WR 23361)
Solvent: Deionised water
A pre-test on toxicity was performed with 8 concentrations between 19.5 and 2500 µg/ml. Without metabolic activation severe toxicity was observed at all the tested concentrations. Therefore, the pre-test was repeated in a lower concentration range (0.16 – 20 µg/ml) at both treatment intervals without metabolic activation.

Results
Although no precipitation was noted in the pre-experiments up to the maximum concentration, precipitation occurred in the first experiment at 1562.5 µg/ml in the presence of metabolic activation. Relevant toxic effects were observed in the first experiment at 30 µg/ml in the absence and at 1562.5 µg/ml in the presence of metabolic activation. In the second experiment, relevant toxic effects were observed at 5.0 µg/ml and above in both cultures.

No reproducible increases were observed in mutant colony numbers/10^6 cells in both experiments up to the maximum concentration with and without metabolic activation. The induction factor exceeded three times the mutant frequency of the corresponding solvent control at the following concentrations: experiment 1: second culture without metabolic activation at 15 µg/ml, experiment 1: second culture with metabolic activation at 1250 and 1562.5 µg/ml, Experiment 2: second culture at 5 µg/ml. However, there were no comparable effects in the parallel cultures and moreover the number of mutant colonies remained well within the historical range of negative and solvent controls.

Conclusion
Under the test conditions used Hydroxyethyl-p-Phenylenediamine Sulfate (WR 23361) did not induce gene mutations at the hprt-locus in V79 cells.

Ref.: 28

In vitro Micronucleus Test

Guideline: OECD 487 (draft 2004)
Species/strain: Human peripheral blood lymphocytes
Replicates: Duplicate cultures in one experiment
Test substance: Hydroxyethyl-p-Phenylenediamine Sulfate (WR 23361)
Solvent: Purified water
Batch: 36/37
Purity: 99.8 area % (by HPLC)
Concentrations: with S9-mix: 600, 1350 and 1800 µg/ml; 3 h treatment 24 hours after mitogen stimulation
without S9-mix: 75, 150 and 300 µg/ml, 20 h treatment 24 hours after mitogen stimulation
Treatment With and without Aroclor induced S9-mix
GLP: in compliance
Study period: 29 November 2004 – 4 January 2005
A preliminary cytotoxicity range-finding experiment was conducted both with and without metabolic activation at 3 and 20 hours treatment both 24 and 48 hours after mitogen stimulation. The experiment included 12 concentrations between 1.222 and 2503 µg/ml.

Results
Based on the range-finding experiment the highest concentration tested was 2503 µg/ml (10 mM) in the pre-test. Treatment of cells commenced approximately 24 hours following mitogen stimulation. In the absence of S9-mix this was for 20 hours followed by a 28-hour recovery period prior to harvest (20+28). Treatment in the presence of S9-mix for 3 hours was followed by a 45-hour recovery period prior to harvest (3+45). The dose levels for micronucleus analysis were selected by evaluating the effect of the test article on the replication index (RI). Micronuclei were analysed at three dose levels. The highest concentrations chosen for analysis, 300 µg/ml in the absence of S9-mix and 1800 µg/ml in the presence of S9-mix, induced approximately 67% and 60% reduction in RI respectively.

Treatment of cultures with the test article in the absence of metabolic activation resulted in frequencies of micronucleated binucleate (MNBN) cells that were higher in a concentration-related manner than those of the concurrent vehicle controls. There was a statistically significant increase in the frequency of MNBN cells after exposure to 150 and 300 µg/mL in the absence of S9, where the respective cytotoxicity values were 54% and 67%.

Treatment of cultures with 1350 and 1800 µg/ml in the presence of S9-mix, associated with 46% and 60% cytotoxicity respectively, resulted in frequencies of MNBN cells that were statistically significantly higher than those of the concurrent vehicle controls. There was a concentration-related increase and the positive response was more distinct compared to the experiment in the absence of metabolic activation. Also much higher concentrations were tested in the presence than in the absence of S9, due to distinct difference in cytotoxicity with and without S9-mix.

Conclusion
Under the test conditions used, the increase in cells with micronuclei indicates genotoxic (clastogenic) activity of hydroxyethyl-p-phenylenediamine sulfate (WR 23361) in cultured human peripheral blood lymphocytes in vitro.

Ref.: 27

### 3.3.6.2 Mutagenicity/Genotoxicity in vivo

**Mammalian Erythrocyte Micronucleus Test**

- **Guideline:** OECD 474 (1997)
- **Species/strain:** NMRI mice
- **Group size:** 6 males per dose group
- **Test substance:** Hydroxyethyl-p-Phenylenediamine Sulfate (WR 23361)
- **Lot no:** 36/37
- **Purity:** 99.8 area% (by HPLC)
- **Dose level:** 25, 50 and 100 mg/kg body weight
- **Route:** Orally, once
- **Vehicle:** Deionised water
- **Sacrifice times:** 24 hours and 48 hours (only for the high dose level).
- **GLP:** In compliance
- **Study period:** 28 February – 6 May 2005

A pre-experiment for acute toxicity was performed using two males and two females at three different doses (100, 150 and 200 mg/kg bw). The mice were examined for acute toxic symptoms at 1 h, 2-4 h, 6 h, 24 h, 30 h and 48 h after administration of 50, 100, 150 and 200 mg/kg bw. Animals died at both 150 and 200 mg/kg bw. 100, 50 and 25 mg/kg bw
were estimated to be suitable. In the main study at least 2000 polychromatic erythrocytes (PCEs) per animal were scored for micronuclei. As no sex-difference in toxicity was found in the pre-test, only male mice were used in the main experiment.

Results
The mean number of polychromatic erythrocytes was not decreased after treatment with the test item as compared to the mean value of PCEs of the vehicle control indicating that the test item had no cytotoxic properties in the bone marrow. The urine of the animals treated with the highest dose had taken the colour of the test item, indicating the bioavailability of the test item, which is confirmed by the toxicokinetics study (see point 3.3.9).

There were no indications of an increase in the frequency of cells with micronuclei at any preparation interval and dose level after administration of the test item. The mean values of micronuclei observed after treatment with A 80 were below or near to the value of the vehicle control group. The positive control (40 mg/kg bw cyclophosphamide) administered orally showed a statistically significant increase of induced micronucleus frequency.

Conclusion
Under the test conditions used, hydroxyethyl-p-phenylenediamine sulfate (WR 23361) did not induce an increase in the number of micronuclei in the bone marrow cells of mice.

Ref.: 29

3.3.7. Carcinogenicity

No data submitted

3.3.8. Reproductive toxicity

3.3.8.1. Two generation reproduction toxicity

No data submitted

3.3.8.2. Teratogenicity

3.3.9. Reproductive toxicity

Taken from SCCP/1124/07

Guideline: OECD guideline 414 (2001)
Species/strain: Rats/CRL:(WI) BR Wistar
Group size: 22 females/group
Test substance: hydroxyethyl-p-phenylenediamine sulfate (Betoxol II), in 1% methylcellulose
Batch: 30/01
Purity: ~99.9%
Dose: 0 (vehicle alone), 10, 30 and 70 mg/kg bw/day
Route: oral, by gavage
Exposure: daily from GD 6 up to GD 20
GLP: in compliance
Study report: 13 October – 10 November 2004

CRL:(WI) BR Wistar rats (22 sperm-positive females/group) were treated daily from GD 6 up to GD20 by gavage with the test item at a dose of 10, 30 and 70 mg/kg bw prepared in 1 % aqueous methylcellulose. These dose levels were based on a preliminary dose-range finding study. The concentrations correspond to a constant treatment volume of 5 ml/kg bw. Control animals were treated with 1 % aqueous methylcellulose.

Cage observations were made twice daily. Individual examination of the animals was performed at least once a day and condition of the animals, including behaviour changes
and signs of overt toxicity, were recorded. Body weight and food consumption was recorded on a regular basis. On GD21 sperm-positive females were asphyxiated by CO₂ followed by cervical dislocation. Foetal weight, placental weight and corrected body weight was determined. The number of implantation sites, corpora lutea, number and position of live foetuses, early and late embryonic death and foetal death were counted. Also gross pathology, histology and foetal examination were performed.

Results
No mortality was observed. In the control and the 10 and 30 mg/kg bw/day dose groups no clinical symptoms were observed. In contrast, clinical symptoms were observed in the 70 mg/kg bw/day dose group. Animals in the 70 mg/kg bw/day dose group showed orange-coloured urine, reduced activity, hunched-position, salivation, piloerection, dyspnoea and reduced righting reflex. In three animals of the 70 mg/kg bw/day dose group, brownish discolouration around the mouth and nose was observed. Body weight and body weight gain in this dose group was significantly reduced in the first week of the treatment. These effects corresponded with clinical signs and reduced food consumption. Gravid uterine weight, corrected body weight and corrected body weight gain was not affected by the test item. Necropsy did not reveal any treatment-related effects. Early embryonic death and post-implantation loss were higher in the 70 mg/kg bw/day dose group as a consequence of maternal toxicity. Foetal body weight and placental weight were similar to control values. Sporadic external, visceral and skeletal alterations were observed, but these effects were not considered treatment-related.

Conclusions
Based on this teratogenicity study a NOAEL for maternal and developmental toxicity of 30 mg/kg/day was determined. No specific compound-related teratogenic effects were observed in this teratogenicity study.

3.3.9. Toxicokinetics

Taken from SCCP/1124/07

Bioavailability across the intestinal barrier

Guideline: Not indicated
Cells: Human intestinal epithelial cell line TC-7, a sub-clone of the Caco-2 cell line
Test substance: hydroxyethyl-p-phenylenediamine sulfate (Betoxol II)
Batch: 36/37
Purity: ~99.8%
Concentration: 50 µM in HBSS buffer containing 1 % DMSO
Incubation time: 60 min
Number of experiments: two independent experiments
GLP: Not in compliance but QAU checked
Study period: 4 April – 2 May 2005

The bioavailability of hydroxyethyl-p-phenylenediamine sulfate across the intestinal barrier was investigated in human intestinal epithelial (TC-7) cells in vitro. The permeability from the apical (A, pH 6.5) to the basolateral (B, pH 7.4) side was investigated at 37° C in 96-well Multiscreen plates with shaking for a 60 min contact time. Analysis of the donor (apical) and receiver (basolateral) samples was done by means of HPLC-MS/MS, and the apparent permeability coefficient (P<sub>app</sub>) was calculated for two independent experiments. <sup>14</sup>C-mannitol (4 µM) was used to demonstrate the integrity of the cell monolayer. Only monolayers with a mannitol permeability of < 2.5 x 10⁻⁶ cm/sec were used. Propranolol and ranitidine were used to validate the experimental conditions.
According to the laboratory’s classification system, a low permeability is considered for test items revealing a $P_{app} < 2 \times 10^{-6}$ cm/sec. A $P_{app}$ of $2 - 20 \times 10^{-6}$ cm/sec and a $P_{app} \geq 20 \times 10^{-6}$ cm/sec classify a substance to have a medium or a high permeability, respectively. Ranitidine, which has a 50 % absorption in humans, was used as low permeability reference compound, as recommended by FDA.

Results
The figures for the reference substances propranolol ($P_{app} = 53.1 \times 10^{-6}$ cm/sec), a high permeability reference compound with about 100 % absorption in humans, and ranitidine ($P_{app} = 0.17 \times 10^{-6}$ cm/sec) revealing an absorption of about 50 % in humans, were well within the typical range of 20 – 60 $\times 10^{-6}$ cm/sec and $< 2 \times 10^{-6}$ cm/sec, respectively. Hydroxyethyl-p-phenylenediamine sulfate revealed a $P_{app}$ of 77.5 $\times 10^{-6}$ cm/sec and thus was classified to be of high permeability, indicating a nearly 100 % absorption from the gastro-intestinal tract. As the absorption from the gastro-intestinal tract is likely to be permeability limited, the high permeability observed in this assay indicates a good absorption hydroxyethyl-p-phenylenediamine sulfate after oral administration.

Ref.: 31

Guideline: /
Species/strain: Sprague Dawley rats
Group size: 3 males and 3 females per group
Method: urine and faeces excretion, carcass and organs analysis after topical application and oral administration by gavage
Test substance: Hydroxyethyl-p-phenylenediamine sulfate (radiolabelled $^{14}$C) in commercial formulations with and without hydrogen peroxide 1.47%
Reference: Hydroxyethyl-p-phenylenediamine sulfate (radiolabelled $^{14}$C) in water 4.88%
Batch: /
Purity: /
Dose levels: 1.63 mg/cm² for the formulations with or without hydrogen peroxide (total area treated 9 cm²)
1.67 mg/cm² for the aqueous solution (total area treated 9 cm²)
3 mg for the aqueous solution (0.3 %) administered orally by gavage
Contact duration: 30 minutes, then washing of the skin and monitoring of the diffusion during 72 hours
Analysis: liquid crystal scintillation
GLP: in compliance

Results
The experimental variability is very high. The mean percutaneous absorption in vivo calculated from the excretion and residual amounts in the carcass is low: 0.063 ± 0.063% of the dose when the substance is applied without hydrogen peroxide, and 0.077 ± 0.074% of the dose when the substance is applied with hydrogen peroxide. This is corresponding to 1.03 to 1.26 $\mu$g/cm². For the aqueous solution, the amount absorbed is 0.124 ± 0.097% of the applied dose (2.07 $\mu$g/cm²). The radioactivity was excreted predominantly via urine (75 to 86 %) than via the faeces (14 to 25 %).
After topical application, the concentrations in the organs were near the detection limit (thyroids, adrenals, brain, testes, bones). After oral administration the test substance is excreted via urine (86 %) and to a less extent via faeces (14 %). Highest concentrations were obtained in thyroids, liver and adrenal. Lowest were detected in the testes, fat and femur.

Conclusion
When considering the residual amount of material present in the skin at 72 hours, the total amount absorbed corresponds to 15 $\mu$g/cm² for the formulation without hydrogen peroxide or to 35 $\mu$g/cm² with hydrogen peroxide. For the aqueous solution, the absorption is
equivalent to 7.5 µg/cm². These data show clearly the influence of the formulation on the absorption of the dye.

Ref.: 32

3.3.10. **Photo-induced toxicity**

3.3.10.1. **Phototoxicity / photoirritation and photosensitisation**

No data submitted

3.3.10.2. **Phototoxicity / photomutagenicity / photoclastogenicity**

No data submitted

3.3.11. **Human data**

See 3.3.3. Skin Sensitisation

3.3.12. **Special investigations**

No data submitted
3.3.13. Safety evaluation (including calculation of the MoS)

CALCULATION OF THE MARGIN OF SAFETY

Hydroxyethyl-p-phenylenediamine sulfate

(oxidative conditions)

Absorption through the skin (mean +1SD) A (µg/cm²) = 3.62 µg/cm²
Skin Area surface SAS (cm²) = 580 cm²
Dermal absorption per treatment SAS x A x 0.001 = 2.10 mg
Typical body weight of human = 60 kg
Systemic exposure dose (SED) SAS x A x 0.001/60 = 0.035 mg/kg bw
No observed adverse effect level NOAEL = 30 mg/kg bw/d

Margin of Safety NOAEL / SED = 857

3.3.14. Discussion

Physico-chemical properties
Hydroxyethyl-p-phenylenediamine sulfate is used as an oxidative hair colouring agent. The intended maximum on-head concentration is 2%. The stability of hydroxyethyl-p-phenylenediamine sulfate in the marketed products is not reported.

General toxicity
The substance was considered to be moderately toxic. The LD₅₀ ranging from 80 to 150 mg/kg bw in male and female rats; In mice, it was 90 mg/kg bw. Based on the local effects in a 28-day study, the NOAEL was set at 250 mg/kg bw/day for both sexes. The NOAEL for systemic effects was set at 1000 mg/kg bw/day. In a 90-day study, the NOAEL was set at 35 mg/kg bw based on an increase in the AST and ALT activities in rats. The NOAEL for maternal and developmental toxicity was set at 30 mg/kg/day. No specific compound-related teratogenic effects were observed. No two generation reproduction study was submitted.

Toxicokinetics
Toxicokinetics were studied in rats in vivo after topical application and oral administration. After dermal application, the total amount absorbed corresponds to 15 µg/cm² for the formulation without hydrogen peroxide or to 35 µg/cm² with hydrogen peroxide, when considering the residual amount of material present in the skin at 72 hours. For the aqueous solution, the absorption was equivalent to 7.5 µg/cm². These data show clearly the influence of the formulation on the absorption of the dye in vivo. In an in vitro test of bioavailability across the intestinal barrier, hydroxyethyl-p-phenylenediamine sulfate was considered to be of high permeability, indicating a nearly 100% absorption from the gastro-intestinal tract. As the absorption from the gastro-intestinal tract is likely to be permeability limited, the high permeability observed in this assay indicates a good absorption hydroxyethyl-p-phenylenediamine sulfate after oral administration.
Opinion on hydroxyethyl-p-phenylenediamine sulfate

**Irritation / sensitisation**
In a test not in compliance with the guidelines, up to 3% 1-β-hydroxyethyl-2,5-diaminobenzene dihydrochloride were not irritant to guinea pig skin. Under the conditions of the test, undiluted hydroxyethyl-p-phenylenediamine sulfate was irritant to rabbit eyes. In the local lymph node assay, hydroxyethyl-p-phenylenediamine sulfate induced a biologically relevant immune response in the vehicle DMSO with an EC3 value of 0.57%. According to the grading scheme used by SCCS (SCCP/0919/05), hydroxyethyl-p-phenylenediamine sulfate is a strong skin sensitiser. Hydroxyethyl-p-phenylenediamine sulfate is a contact allergen in man.

**Dermal absorption**
In a well performed in vitro percutaneous study using human skin (12 chambers from 6 donors per experiment) the amount of hydroxyethyl-p-phenylenediamine sulfate considered bioavailable from a 2% use application was 3.62 (mean + 1SD) μg/cm² under oxidative conditions and 3.17 (mean + 1SD) μg/cm² under non-oxidative conditions.

**Mutagenicity / genotoxicity**
The genotoxicity is sufficiently investigated for the three types of genotoxic endpoints: gene mutation, structural and numerical chromosome aberration. Hydroxyethyl-p-phenylenediamine sulfate was negative in the bacterial gene mutation test as well as in the in vitro gene mutation test in mammalian cells. Positive results were reported in the in vitro micronucleus test. As this clastogenic effects found in vitro was not confirmed in an in vivo bone marrow micronucleus test hydroxyethyl-p-phenylenediamine sulfate itself can be considered to have no in vivo genotoxic potential and additional tests are unnecessary. To reach a definitive conclusion, appropriate tests with hydroxyethyl-p-phenylenediamine sulfate in combination with hydrogen peroxide have to be provided.

**Carcinogenicity**
No data submitted

**4. CONCLUSION**
The SCCS is of the opinion that the use of hydroxyethyl-p-phenylenediamine sulfate itself as an ingredient in oxidative hair dyes at a maximum concentration on-head of 2% does not pose a risk to the health of the consumer, apart from its strong sensitising potential.

Hydroxyethyl-p-phenylenediamine sulfate is a strong sensitiser.

Hydroxyethyl-p-phenylenediamine sulfate itself has no mutagenic potential in vivo. However, studies on genotoxicity/mutagenicity in finished hair dye formulations should be undertaken following the relevant SCCNFP/SCCP opinions and in accordance with its Notes of Guidance.

**5. MINORITY OPINION**
Not applicable
6. REFERENCES

1. Tenberken-Pötzsch, B.; Identity, stability and purity test Hydroxyethyl-p-phenylenediamine sulfate (Betoxol II); WELLA AG; 2000
2. Dougoud, P.; Certificate of analysis for Hydroxyethyl-p-phenylenediamine sulfate (A080); COSMITAL SA; 2005
3. Geffke, Th.; Partition coefficient (n-octanol / water) using High Performance Liquid Chromatography (HPLC); NOACK; 2003
4. Geffke, Th.; Sieve analysis; NOACK; 2003
5. Geffke, Th.; Water solubility; NOACK; 2003
6. Lange, J.; Prediction of the pKa-value; NOACK; 2004
7. Geffke, Th.; Melting point / melting range; NOACK; 2003
8. Geffke, Th.; Boiling point; NOACK; 2003
9. Geffke, Th.; Determination of the density; NOACK; 2003
10. Smeykal, H.; Vapour pressure; SIEMENS AXIVA GMBH & CO. KG; 2002
11. Schneider, S.; Determination of the surface tension of an aqueous solution (1 g/l) of Betoxol II in accordance with OECD-Guideline 115 [and according to EEC-Guideline A.5]; ALLESSA CHEMIE GMBH; 2003
12. Geffke, Th.; Flammability of solids; NOACK; 2003
13. Smeykal, H.; Explosive properties; SIEMENS AXIVA GMBH & CO. KG; 2002
14. Smeykal, H.; Auto-flammability (solids - determination of relative self-ignition temperature); SIEMENS AXIVA GMBH & CO. KG; 2002
15. Geffke, Th.; Oxidizing properties of solids; NOACK; 2003
16. Scientific Committee on Consumer Products SCCP Opinion on Hydroxyethyl-p-phenylenediamine Sulfate Colipa no A80; SCCP; 2004
17. Büsching, J.; Acute oral toxicity test of 1-ß-hydroxyethyl-2,5-diaminobenzene dihydrochloride; WELLA AG; 1979
18. Klein, W.; Acute oral toxicity of "Betoxol" in mice; SEIBERSDORF; 1990
19. Weide, J.; Skin compatibility test in the albino guinea pig with 1-ß-Hydroxyethyl-2,5-diaminobenzene dihydrochloride; WELLA AG; 1985
20. van Huygevoort, A. H. B. M.; Acute eye irritation/corrosion study with Betoxol in the rabbit; NOTOX; 2000
21. Contact sensitisation: Classification according to potency; ECETOC; 2003
22. Albrecht, A.; Test for sensitization (Local lymph node assay - LLNA) with Betoxol II; BIOSERVICE; 2001
23. Beck, H.; Cutaneous absorption of 1.5% Hydroxyethyl-p-phenylenediamine sulfate (=WR23361) in a typical hair dye formulation with peroxide and reaction partner through pig skin in vitro; COSMITAL SA; 2005
25. Szakonyi, I. P.; Repeated dose 90-day oral toxicity study of Hydroxyethyl-p-phenylenediamine sulfate (Betoxol II, WR 23361) in CRL: (WI) BR rats; LAB INTERNATIONAL RESEARCH CENTRE HUNGARY LTD.; 2005
26. Sokolowski, A.; Salmonella typhimurium reverse mutation assay with Hydroxyethyl-p-phenylenediamine sulfate (WR 23361); RCC-CCR; 2005
27. Clare, G.; Hydroxyethyl-p-phenylenediamine sulfate (WR 23361): Induction of micronuclei in cultured human peripheral blood lymphocytes; COVANCE; 2005
28. Wollny, H.-E.; Gene mutation assay in Chinese hamster V79 cells in vitro (V79 / HPRT) with Hydroxyethyl-p-phenylenediamine sulfate (WR 23361); RCC-CCR; 2005
29. Honarvar, N.; Micronucleus assay in bone marrow cells of the mouse with Hydroxyethyl-p-phenylenediamine Sulfate (WR23361); RCC-CCR; 2005
30. Pál-Kutas, K.; Teratology study: Prenatal developmental study of Hydroxyethyl-p-Phenylenediamine Sulfate (Betoxol II, WR 23361) in CRL(WI) BR rats; Lab International Research Centre Hungary LTD.; 2005
31. Kennedy, K. J.; ADME: A-B permeability - Study of Hydroxyethyl-p-phenylenediamine sulfate; CEREP; 2005
32. Reindl, E.; Toxicokinetics of "2,5-Diaminophenylethanol-Sulfate"; Seibersdorf; 1992
33. Kock, M.; Retrospective clinical study on skin compatibility of Hydroxyethyl-p-Phenylenediamine sulfate - containing hair colourant products in patients allergic to p-Phenylenediamine or Toluene-2,5-Diamine; WELLA AG; 2005
34. König, P.; Data base search for references for A080 - Hydroxyethyl-p-phenylenediamine sulfate: 93841-25-9; WELLA AG; 2005

Submission I (1989)


Submission November 2009


Additional references

SCCP/0919/05. Memorandum: Classification and categorization of skin sensitisers and grading of test reactions. Adopted by the SCCP during the 5th plenary meeting of 20 September 2005.